Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Eric Rowinsky, M.D.

Executive Chairman

Eric K. Rowinsky, M.D., is the Executive Chairman of Rgenix and Chair of its Clinical Advisory Board. Dr. Rowinsky is principally focused on the comprehensive development and registration strategies of cancer therapeutics of all types. Dr. Rowinsky obtained his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996-2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC Endowed Chair for Early Drug Development from 1996-2005 and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996-2006.

From 2005-2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs. From 2007-2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. Dr. Rowinsky and his team at ImClone were responsible for approvals of cetuximab (Erbitux) in various indications, as well as ramucirumab in four indications and necitumumbab in one indication. Dr. Rowinsky was the Head of Research and Development, Executive Vice President, and Chief Medical Officer at Stemline Therapeutics from 2012-2015. He is also an Adjuvant Professor of Medicine at New York University School of Medicine. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies, including a wide variety of cytotoxic and targeted anticancer therapeutics.

Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 310 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI. Dr. Rowinsky is on the board of directors of several public companies, including Biogen Idec Inc., Navidea Inc., Bind Therapeutics, and Fortress Biotech Inc.